295 related articles for article (PubMed ID: 28281549)
1. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms.
Weissferdt A; Fujimoto J; Kalhor N; Rodriguez J; Bassett R; Wistuba II; Moran CA
Mod Pathol; 2017 Jun; 30(6):826-833. PubMed ID: 28281549
[TBL] [Abstract][Full Text] [Related]
2. PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus.
Bagir EK; Acikalin A; Avci A; Gumurdulu D; Paydas S
J Clin Pathol; 2018 Jul; 71(7):637-641. PubMed ID: 29439008
[TBL] [Abstract][Full Text] [Related]
3. PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus.
Marchevsky AM; Walts AE
Hum Pathol; 2017 Feb; 60():16-23. PubMed ID: 27746267
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological analysis of thymic malignancies with a consistent retrospective database in a single institution: from Tokyo Metropolitan Cancer Center.
Okuma Y; Hosomi Y; Watanabe K; Yamada Y; Horio H; Maeda Y; Okamura T; Hishima T
BMC Cancer; 2014 May; 14():349. PubMed ID: 24885581
[TBL] [Abstract][Full Text] [Related]
5. Tumor immunity is related to
Imai H; Kaira K; Hashimoto K; Nitanda H; Taguchi R; Yanagihara A; Umesaki T; Yamaguchi O; Mouri A; Kawasaki T; Yasuda M; Kobayashi K; Sakaguchi H; Kuji I; Kagamu H
Cancer Med; 2021 Sep; 10(18):6317-6326. PubMed ID: 34363337
[TBL] [Abstract][Full Text] [Related]
6. Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach.
Berardi R; Goteri G; Brunelli A; Pagliaretta S; Paolucci V; Caramanti M; Rinaldi S; Refai M; Pompili C; Morgese F; Torniai M; Marcantognini G; Ricci G; Mazzanti P; Onofri A; Bianchi F; Sabbatini A; Cascinu S
Expert Opin Ther Targets; 2020 Sep; 24(9):937-943. PubMed ID: 32662701
[TBL] [Abstract][Full Text] [Related]
7. Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma.
Owen D; Chu B; Lehman AM; Annamalai L; Yearley JH; Shilo K; Otterson GA
J Thorac Oncol; 2018 Aug; 13(8):1204-1212. PubMed ID: 29702286
[TBL] [Abstract][Full Text] [Related]
8. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
Tiseo M; Damato A; Longo L; Barbieri F; Bertolini F; Stefani A; Migaldi M; Gnetti L; Camisa R; Bordi P; Buti S; Rossi G
Lung Cancer; 2017 Feb; 104():24-30. PubMed ID: 28212996
[TBL] [Abstract][Full Text] [Related]
9. Thymoma and thymic carcinoma in children and adolescents: a report from the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT).
Stachowicz-Stencel T; Orbach D; Brecht I; Schneider D; Bien E; Synakiewicz A; Rod J; Ferrari A; Cecchetto G; Bisogno G
Eur J Cancer; 2015 Nov; 51(16):2444-52. PubMed ID: 26259494
[TBL] [Abstract][Full Text] [Related]
10. Expression of c-Jun, p73, Casp9, and N-ras in thymic epithelial tumors: relationship with the current WHO classification systems.
Ma Y; Li Q; Cui W; Miao N; Liu X; Zhang W; Zhang C; Wang J
Diagn Pathol; 2012 Sep; 7():120. PubMed ID: 22974165
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature.
Guleria P; Husain N; Shukla S; Kumar S; Parshad R; Jain D
Ann Diagn Pathol; 2018 Jun; 34():135-141. PubMed ID: 29661720
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression level in different thymoma stages and thymic carcinoma: a meta-analysis.
Chen HF; Wu LX; Li XF; Zhu YC; Pan WW; Wang WX; Xu CW; Huang JH; Wu MH; Du KQ
Tumori; 2020 Aug; 106(4):306-311. PubMed ID: 32366210
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.
Yokoyama S; Miyoshi H; Nakashima K; Shimono J; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Ohshima K
Clin Cancer Res; 2016 Sep; 22(18):4727-34. PubMed ID: 27166394
[TBL] [Abstract][Full Text] [Related]
14. Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy.
Katsuya Y; Horinouchi H; Asao T; Kitahara S; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Watanabe S; Tsuta K; Ohe Y
Lung Cancer; 2016 Sep; 99():4-10. PubMed ID: 27565906
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.
Katsuya Y; Fujita Y; Horinouchi H; Ohe Y; Watanabe S; Tsuta K
Lung Cancer; 2015 May; 88(2):154-9. PubMed ID: 25799277
[TBL] [Abstract][Full Text] [Related]
16. Programmed Death-ligand 1 (PD-L1) Expression in Thymic Epithelial Tumors.
Bedekovics J; Beke L; Mokanszki A; Szilagyi S; Mehes G
Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):1-9. PubMed ID: 30499814
[TBL] [Abstract][Full Text] [Related]
17. Thymoma patients with pleural dissemination: nationwide retrospective study of 136 cases in Japan.
Okuda K; Yano M; Yoshino I; Okumura M; Higashiyama M; Suzuki K; Tsuchida M; Usuda J; Tateyama H
Ann Thorac Surg; 2014 May; 97(5):1743-8. PubMed ID: 24657034
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic Features of Thymoma With the Expression of Programmed Death Ligand 1.
Hakiri S; Fukui T; Mori S; Kawaguchi K; Nakamura S; Ozeki N; Kato T; Goto M; Yatabe Y; Yokoi K
Ann Thorac Surg; 2019 Feb; 107(2):418-424. PubMed ID: 30312607
[TBL] [Abstract][Full Text] [Related]
19. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
Arbour KC; Naidoo J; Steele KE; Ni A; Moreira AL; Rekhtman N; Robbins PB; Karakunnel J; Rimner A; Huang J; Riely GJ; Hellmann MD
PLoS One; 2017; 12(8):e0182665. PubMed ID: 28771603
[TBL] [Abstract][Full Text] [Related]
20. Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma.
Wei YF; Chu CY; Chang CC; Lin SH; Su WC; Tseng YL; Lin CC; Yen YT
Lung Cancer; 2018 Nov; 125():35-42. PubMed ID: 30429036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
